-
Review
March 9, 2023
- Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
- Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka
- Clin Mol Hepatol. 2023;29(4):851-868.
Review
March 9, 2023
Review
March 14, 2023
Review
April 13, 2023
Review
May 25, 2023
Review
June 5, 2023
Review
August 14, 2023
Review
August 29, 2023
Original Article
July 5, 2023
Original Article
September 11, 2023
Original Article
July 5, 2023
Original Article
August 29, 2023
This archive contains links to the full-text of all issues of Clin Mol Hepatol.
![]() |
First decision
09 Days
Publication after acceptance
07 Days
*Last 12 months
Viewed By 4811 |
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |
Viewed By 4774 |
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy |
Viewed By 3801 |
MAFLD: How is it different from NAFLD? |
Viewed By 2633 |
Management of refractory ascites |
Viewed By 2472 |
Global incidence and prevalence of nonalcoholic fatty liver disease |
Cited By 131 |
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease |
Cited By 78 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma |
Cited By 60 |
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? |
Cited By 55 |
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis |
Cited By 55 |
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |